Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Drops By 74.3%

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 117,500 shares, a decrease of 74.3% from the December 31st total of 457,500 shares. Currently, 0.8% of the company’s shares are sold short. Based on an average daily volume of 3,580,000 shares, the days-to-cover ratio is presently 0.0 days.

Virpax Pharmaceuticals Trading Up 0.1 %

VRPX traded up $0.00 during midday trading on Friday, reaching $0.31. 466,286 shares of the company’s stock traded hands, compared to its average volume of 470,612. Virpax Pharmaceuticals has a 52 week low of $0.23 and a 52 week high of $5.48. The firm has a fifty day moving average of $0.36 and a two-hundred day moving average of $0.67.

Analyst Ratings Changes

Separately, Maxim Group reissued a “hold” rating on shares of Virpax Pharmaceuticals in a report on Wednesday, October 9th.

Institutional Trading of Virpax Pharmaceuticals

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new position in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned approximately 1.17% of Virpax Pharmaceuticals as of its most recent filing with the SEC. Institutional investors and hedge funds own 32.23% of the company’s stock.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.